SummitTX Capital L.P. Has $4.35 Million Stock Holdings in Vaxcyte, Inc. $PCVX

SummitTX Capital L.P. boosted its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 403.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 74,842 shares of the company’s stock after purchasing an additional 59,973 shares during the quarter. SummitTX Capital L.P.’s holdings in Vaxcyte were worth $4,349,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. EverSource Wealth Advisors LLC lifted its holdings in shares of Vaxcyte by 33.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after buying an additional 184 shares during the last quarter. Meeder Advisory Services Inc. grew its stake in shares of Vaxcyte by 2.9% in the first quarter. Meeder Advisory Services Inc. now owns 8,335 shares of the company’s stock worth $484,000 after acquiring an additional 231 shares during the last quarter. CWM LLC increased its position in Vaxcyte by 9.0% during the fourth quarter. CWM LLC now owns 2,840 shares of the company’s stock worth $131,000 after acquiring an additional 234 shares during the period. Harbor Capital Advisors Inc. raised its stake in Vaxcyte by 0.8% during the 4th quarter. Harbor Capital Advisors Inc. now owns 31,274 shares of the company’s stock valued at $1,443,000 after purchasing an additional 252 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in Vaxcyte by 7.0% in the 1st quarter. Principal Financial Group Inc. now owns 5,275 shares of the company’s stock valued at $307,000 after purchasing an additional 343 shares during the period. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Wall Street Zen lowered shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Zacks Research lowered Vaxcyte from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $86.00.

Insider Transactions at Vaxcyte

In other news, COO Jim Wassil sold 2,250 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $56.33, for a total value of $126,742.50. Following the transaction, the chief operating officer directly owned 156,760 shares of the company’s stock, valued at $8,830,290.80. The trade was a 1.42% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Grant Pickering sold 2,000 shares of the business’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $55.23, for a total value of $110,460.00. Following the completion of the transaction, the chief executive officer directly owned 134,215 shares in the company, valued at approximately $7,412,694.45. This represents a 1.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 75,448 shares of company stock valued at $4,091,197. 3.30% of the stock is owned by insiders.

Vaxcyte Price Performance

Shares of PCVX stock opened at $55.50 on Tuesday. The stock’s fifty day simple moving average is $52.71 and its 200 day simple moving average is $54.71. The firm has a market cap of $8.01 billion, a price-to-earnings ratio of -8.07 and a beta of 1.22. Vaxcyte, Inc. has a one year low of $29.08 and a one year high of $65.00.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($2.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same period in the previous year, the business posted ($1.04) earnings per share. On average, research analysts anticipate that Vaxcyte, Inc. will post -7.91 earnings per share for the current year.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.